Residency · Residency · Anesthesiology

Anesthesia for the Patient with Chronic Kidney Disease

Introduction

Chronic kidney disease (CKD) affects over 15% of the adult population and is classified into five stages based on glomerular filtration rate (GFR). Patients with CKD present multisystem derangements that profoundly impact anesthetic management, including volume overload, electrolyte imbalances, anemia, coagulopathy, and altered drug pharmacokinetics. End-stage renal disease (ESRD, Stage 5, GFR less than 15 mL/min) patients on dialysis represent the highest-risk subset.

Classification of CKD

Systemic Effects of CKD

Cardiovascular

Hypertension is present in more than 80% of CKD patients and is driven by both volume-dependent and renin-mediated mechanisms. Left ventricular hypertrophy develops from chronic hypertension and volume overload, with diastolic dysfunction being a common consequence. Accelerated atherosclerosis is the leading cause of death in ESRD, with coronary artery disease prevalence 3 to 5 times that of the general population. Uremic pericarditis may cause pericardial effusion and tamponade and is an indication for urgent dialysis. Autonomic dysfunction manifests as impaired baroreceptor reflexes, orthostatic hypotension, and reduced heart rate variability.

Hematologic

Anemia of CKD results from decreased erythropoietin production, with a target hemoglobin of 10 to 11 g/dL maintained with erythropoiesis-stimulating agents (ESAs). Platelet dysfunction from uremic toxins impairs platelet adhesion and aggregation, prolonging bleeding time despite a normal platelet count. Impaired immune function increases susceptibility to infection, making strict aseptic technique essential.

Metabolic and Electrolyte

Hyperkalemia is the most dangerous electrolyte abnormality and is exacerbated by acidosis, tissue injury, succinylcholine, and blood transfusion. Metabolic acidosis results from decreased renal acid excretion, with compensatory hyperventilation. Hypocalcemia and hyperphosphatemia lead to secondary hyperparathyroidism and renal osteodystrophy. Sodium abnormalities (hyponatremia or hypernatremia) depend on volume status and dialysis adequacy. Hypermagnesemia from decreased renal excretion potentiates neuromuscular blockade.

Pulmonary

Pulmonary edema occurs from volume overload between dialysis sessions. Pleural effusions are common in ESRD. Uremic pleuritis may cause pleuritic chest pain.

Gastrointestinal

Gastroparesis from autonomic neuropathy leads to delayed gastric emptying, warranting consideration of full-stomach precautions. GI bleeding risk is increased by uremic platelet dysfunction. Uremic fetor presents as an ammonia-like breath odor.

Neurologic

Uremic encephalopathy presents with confusion, asterixis, and seizures and is an indication for dialysis. Peripheral sensorimotor neuropathy may affect positioning and regional anesthesia planning. Autonomic neuropathy contributes to gastroparesis and orthostatic hypotension.

Preoperative Assessment

Key Evaluations

Dialysis history should document the last session (ideally within 24 hours of surgery), the type (hemodialysis versus peritoneal), adequacy, and dry weight. Electrolyte assessment is paramount, with potassium levels greater than 5.5 mEq/L requiring correction before elective surgery. Volume status is assessed for hypervolemia by checking for edema, jugular venous distension, pulmonary crackles, and weight above dry weight. Hemoglobin is evaluated with transfusion considered if levels fall below 7 to 8 g/dL for major surgery, though unnecessary transfusion should be avoided to prevent sensitization in future transplant candidates. Vascular access must be identified, and the AV fistula or graft must be protected by placing no blood pressure cuffs, IVs, or tourniquets on that extremity. ECG assessment looks for LVH, hyperkalemia signs (peaked T waves, widened QRS), and ischemic changes. Echocardiography is obtained if heart failure symptoms or new cardiac concerns are present.

Medication Review

Most antihypertensives are continued, with consideration given to holding ACE inhibitors and ARBs on the day of surgery. Metformin is held if any residual renal function exists. Phosphate binders, ESAs, and immunosuppressants (if the patient is a transplant candidate) are reviewed. Dosing of renally cleared medications must be adjusted.

Intraoperative Management

Monitoring

Standard ASA monitors are supplemented with an arterial line for major surgery. Central venous pressure monitoring is added for procedures involving large fluid shifts. The AV fistula must be protected: no blood pressure cuff, IV, or arterial line is placed on the fistula extremity, and patency is verified by checking for thrill and bruit before and after positioning.

Induction and Airway

Rapid sequence induction should be considered if gastroparesis or recent oral intake is present. Succinylcholine is relatively contraindicated when potassium exceeds 5.0 mEq/L because it causes a 0.5 to 1.0 mEq/L rise in serum potassium; rocuronium with sugammadex is a safer alternative for rapid sequence induction. Propofol and etomidate are both acceptable induction agents, though doses should be reduced due to hypoalbuminemia and decreased protein binding.

Maintenance

All volatile agents are acceptable with no significant renal toxicity at clinical concentrations; historical concerns about sevoflurane and Compound A have not been validated clinically. For opioids, morphine should be avoided because its active metabolite M6G accumulates, and meperidine is contraindicated because normeperidine causes seizures. Fentanyl, sufentanil, and remifentanil are preferred. Among neuromuscular blockers, cisatracurium is ideal because of Hofmann elimination. Rocuronium and vecuronium have prolonged duration in ESRD and should be used with neuromuscular monitoring and sugammadex availability. Quantitative neuromuscular monitoring is essential to avoid residual paralysis.

Fluid and Electrolyte Management

Potassium-containing fluids should be avoided; Lactated Ringer's contains 4 mEq/L of potassium. Normal saline is commonly used, though large volumes cause hyperchloremic acidosis. Plasmalyte contains 5 mEq/L of potassium but carries a lower risk of acidosis. Potassium should be monitored intraoperatively with point-of-care testing. Hyperkalemia is treated with calcium chloride or gluconate for membrane stabilization, insulin with glucose, sodium bicarbonate, and hyperventilation, with dialysis as the definitive treatment.

Hemodynamic Management

CKD patients are often volume-overloaded yet preload-dependent due to diastolic dysfunction. Vasopressors such as phenylephrine and norepinephrine may be needed rather than excessive fluid administration. Goal-directed fluid therapy with dynamic parameters (pulse pressure variation, stroke volume variation) is used when appropriate.

Regional Anesthesia Considerations

Neuraxial anesthesia is generally safe, though platelet function should be checked because bleeding time may be prolonged despite a normal count. DDAVP at 0.3 mcg/kg can improve platelet function if needed. Peripheral nerve blocks are excellent for AV fistula surgery and vascular access procedures, though uremic neuropathy may alter block characteristics. Reduced local anesthetic protein binding leads to higher free drug levels, so doses should be reduced slightly. Regional techniques provide opioid-sparing analgesia, which is particularly advantageous in CKD.

Postoperative Considerations

Electrolytes, especially potassium, are monitored in the immediate postoperative period. Postoperative dialysis timing is coordinated with nephrology. Analgesic dosing is adjusted to avoid morphine and NSAIDs (which are nephrotoxic, increase GI bleeding risk, and affect platelets). Acetaminophen is safe and should be used as a first-line analgesic. Monitoring for fluid overload and pulmonary edema continues postoperatively.

Key Clinical Pearls

The AV fistula must be protected at all costs, with no blood pressure cuffs, IVs, blood draws, or arterial lines placed on the access extremity. Potassium should be checked before induction, and levels greater than 5.5 mEq/L require correction before elective surgery. Succinylcholine should be avoided when potassium is elevated, and rocuronium with sugammadex provides a safer RSI alternative. Morphine and meperidine are contraindicated in ESRD due to active metabolite accumulation. CKD patients are often hypervolemic but functionally preload-dependent, making vasopressors frequently more appropriate than volume loading. Blood transfusions should be minimized in potential transplant candidates to reduce HLA sensitization.

References

1. Craig RG, Hunter JM. Recent developments in the perioperative management of adult patients with chronic kidney disease. Br J Anaesth. 2008;101(3):296-310.
2. Schmid S, Jungwirth B. Anaesthesia for renal transplant surgery: an update. Eur J Anaesthesiol. 2012;29(12):552-558.
3. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150.
4. Wagener G, Bhatt NR. Anesthetic management of patients with chronic kidney disease. Int Anesthesiol Clin. 2020;58(2):37-44.

Read this lecture as Markdown